Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.66 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.54 |
| ▸ | SRC | P12931 | 5/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.47 |
| ▸ | ABL1 | P00519 | 3/20 | 0.47 |
| ▸ | EGFR | P00533 | 3/20 | 0.47 |
| ▸ | HCK | P08631 | 3/20 | 0.47 |
| ▸ | KDR | P35968 | 3/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.47 |
| ▸ | MTOR | P42345 | 3/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.47 |
| ▸ | PRKDC | P78527 | 3/20 | 0.47 |
| ▸ | MAT2A | P31153 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21581808 | 0.80 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL21731321 | 0.80 | ADORA2A (0.53) | ADORA2AADORA1ADORA3ADORA2BMAT2A | |
| SCHEMBL21731054 | 0.77 | ADORA2A (0.66) | ADORA2AADORA1ADORA3ADORA2BSRC | |
| SCHEMBL21731205 | 0.77 | ADORA2A (0.44) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL29781406 | 0.77 | NPC1 (0.49) | ADORA2AADORA1ADORA3ADORA2BSRC | |
| SCHEMBL21731119 | 0.77 | ADORA2A (0.52) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL21731117 | 0.77 | ADORA2A (0.44) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL21731313 | 0.77 | ADORA2A (0.40) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL21731050 | 0.77 | ADORA2A (0.64) | ADORA2AADORA1ADORA2BPOLB | |
| SCHEMBL21731011 | 0.76 | ADORA1 (0.48) | ADORA2AADORA1ADORA3ADORA2BNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3611174-B1 | [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR | MEDSHINE DISCOVERY INC (CN) | 2022-06-08 | — | — | EP | disclosed |
| US-11117899-B2 | [1,2,4]triazolo[1,5-c]pyrimidine derivative as A2A receptor inhibitor | MEDSHINE DISCOVERY INC. (CN) | 2021-09-14 | — | — | US | disclosed |
| US-11066411-B2 | — | — | 2021-07-20 | — | — | US | disclosed |
| US-20200131184-A1 | [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2020-04-30 | — | — | US | disclosed |
| EP-3611174-A1 | [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR | Medshine Discovery Inc. (CN) | 2020-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11117899-B2 | [1,2,4]triazolo[1,5-c]pyrimidine derivative as A2A receptor inhibitor | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885ADORA3 3/4885 |
| US-11066411-B2 | — | ADORA2A, ADORA1, ADORA2B | ADORA2A 1/4885ADORA1 2/4885ADORA3 4/4885 |
| US-20200131184-A1 | [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA1 2/4885ADORA3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.